Premium
P4–408: Early real–world clinical experience with memantine treatment for Alzheimer's disease in the United States
Author(s) -
Shaughnessy Lynn W.,
Locascio Joseph J.,
Atri Alireza
Publication year - 2006
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2006.05.2150
Subject(s) - memantine , donepezil , medicine , clinical trial , placebo , dementia , alzheimer's disease , randomized controlled trial , disease , pediatrics , alternative medicine , pathology
terol and saturated fats with amyloid(A ) deposition and development of AD. Yet, these studies did not examine high fat diets in combination with reduced carbohydrate intake. Methods: Starting at three months of age, two groups of female transgenic mice carrying the ‘London‘ APP mutation (APP/V717I) were fed either, a standard diet (SD) composed of high carbohydrate / low fat chow, or a ketogenic diet (KD) composed of very low carbohydrate / high saturated fat chow for 43 days. Results: Animals fed the KD exhibited greatly elevated serum ketone body levels, as measured by -hydroxybutyrate (3.85 2.6 mM), compared to SD fed animals (0.29 0.06 mM). In addition, animals fed the KD lost body weight (SD 22.2 0.6 g vs. KD 17.5 1.4 g, p 0.0067). In contrast to earlier studies, the brief KD feeding regime significantly reduced total brain A levels by approximately 25%. Conclusions: Therefore, dietary strategies aimed at reducing A levels should take into account interactions of dietary components and the metabolic outcomes, in particular, levels of carbohydrates, total calories, and the presence of ketone bodies should be considered.